secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001213900-25-120668
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX subsidiary BiomX Ltd files for insolvency; Phase 2b study discontinued
----------------------------------------------------------------------------

- Phase 2b study discontinued Dec 8 due to resource constraints exceeding available funds.
- Dec 11: Board of BiomX Ltd authorized filing for insolvency proceedings in Israel.
- Company evaluating strategic options; continues BX011 program via Adaptive Phage Therapeutics.
- Limited financial resources cited as primary reason for study discontinuation and insolvency filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025120668/0001213900-25-120668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025120668/ea0269336-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-120668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer